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Abstract 28 
The expression of the hypoxia-inducible protein erythropoietin in tumour cells correlates with levels 29 
of tumour hypoxia. Our aim was to look for an interrelation of directly measured oxygenation levels, 30 
the presence of tissue erythropoietin and its receptor. Data of tumour oxygenation status, plasma and 31 
tissue erythropoietin and its receptor in a group of spontaneously occurring tumours in 15 dogs were 32 
collected. Polarographic tumour oxygen partial pressure measurements were obtained and data were 33 
correlated. 34 
Significant positive correlations were found between tissue erythropoietin and the percentages of pO2
Our results show that a co-expression of erythropoietin receptor and its ligand in spontaneous canine 38 
tumours exists, that the level of hypoxia in tumour cells correlates with the level of tissue 39 
erythropoietin and suggest the need to be quantitatively and functionally tested as novel prognostic 40 
biological parameters in neoplastic tissues.  41 
 35 
values ≤ 10 mmHg. Multivariate analysis revealed no parameters influencing plasma erythropoietin 36 
levels. 37 
 42 
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Introduction  45 
It has been shown, that Epo1
Tumour hypoxia, a factor associated with tumour aggressiveness, treatment resistance and poor 52 
prognosis itself (5-7), seems to be one of the up-regulators and modulators of Epo production as a 53 
direct result of hypoxia inducible factor-1 activation (4, 8). It has been shown in vivo and in vitro that 54 
Epo and EpoR expression can be partially colocalized with tumour tissue hypoxia (3, 9). However, 55 
these studies were assessing the relationship of tumour hypoxia and the expression of EpoR and its 56 
ligand in a semiquantitative way. In the present study, we hypothesized that hypoxic tumours have 57 
high tissue Epo expression and that this relationship can be directly shown by correlating invasive 58 
polarographic oxygen measurements with quantitative analyses of tumour tissue Epo. 59 
 and EpoR are not only produced and expressed by various non-46 
erythroid tissues, but also by human malignancies (1-3). As a pleiotropic cytokine, Epo on one hand 47 
acts as a haematopoietic growth factor, but it also exerts proangiogenic and tissue-protective effects in 48 
other organs. Activation of Epo-EpoR signalling pathways in cancer cells may be followed by 49 
modulation of tumour environment such as angiogenesis, increased proliferation and changes in 50 
apoptotic ability (4). Furthermore response to treatment such as chemoradiation may be influenced.  51 
 60 
Materials and Methods 61 
 Patients. Fifteen canine patients with tumours of various histologies, enrolled in a tumour hypoxia 62 
study approved by the Swiss Veterinary authorities were included in this study. The primary tumours 63 
were localized in the oral cavity in 11 patients, on the extremities and skull in two patients each. Two 64 
or more quick frozen tumour tissue specimens were available from each patient. The site, histological 65 
diagnosis and tumour volumes are listed in Table 1. 66 
 67 
Measurement of tumour hypoxia. Tumour oxygen partial pressure measurements were 68 
performed as previously described in dogs (10), using an pO2-Histograph (Helzel Medical Systems, 69 
Kaltenkirchen, Germany). The needle electrode was placed within the tumour tissue under ultrasound 70 
guidance (ATL 5000, Philips Medical Systems, Zurich, Switzerland). At least three different electrode 71 
tracks and a minimum of 50 recorded values were acquired for reliable statistical analysis (11). 72 
Oxygenation status of individual tumours was described using the median pO2 and the hypoxic 73 
fractions (% of pO2 values ≤ 10 mmHg, ≤ 5 mmHg and ≤ 2.5 mmHg, respectively). Tumour size was 74 
measured with callipers and the volume was calculated based on the formula: π/6 x height x width x 75 
depth, which approximately describes the volume of an ellipsoid. The hypoxic subvolume (HSV) was 76 
calculated by the formula: volume (ccm) x hypoxic fraction (% of pO2
 78 
-values ≤ 5 mmHg).  77 
Sample preparation. Tumour biopsies were taken immediately after the oxygen measurements, 79 
right before the start of radiation therapy and the samples were quick frozen in liquid nitrogen. The 80 
samples were stored at –80°C until further use. For protein extraction the specimens were transferred 81 
directly from –80°C in 1ml of ice cold homogenization buffer (0.27 M Sucrose, 2 mM EDTA pH 8.0, 82 
1 % NP-40, 1 mM PMSF, 1 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin, 1 mM NaVa) in a 5 cm2 83 
dounce homogenizer on ice: tissue was dounced 25 times with a pestle, and than transferred on a 84 
sucrose cushing. Tissue lysate was centrifuged for 10 min at 4°C at 3000 rpm and protein 85 
concentration was measured. For analysis of plasma Epo three millilitres of blood were collected into 86 
sterile CTAD tubes (Beckton and Dickinson Vacutainer System, France) and placed on ice. The tubes 87 
were centrifuged within 15 min at 2500* g for 30 min at 4°C. The resulting plasma was separated and 88 
stored immediately at –80o
 90 
C. 89 
RIA. Plasma and tissue erythropoietin was measured using a commercial kit (Epo-TracTM 125
 95 
I RIA 91 
kit, DiaSorin, USA) applying the method previously described by Glaus et al. (12). Tissue Epo was 92 
measured in normal tissues in order to establish control values in a series of canine tissues, such as 93 
lymphnode, liver, muscle and uterus. 94 
Western blotting. Epo receptor status of analysed tumour specimens was performed by 96 
immunoblotting technique. Therefore, protein samples (100 µg/well) were resolved by denaturing 97 
electrophoresis on 10% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane 98 
(Whatman GmbH, Dassel, Germany). The membrane was blocked for 2 h in 4% nonfat dry milk in 99 
PBS, 0.5% Tween 20, rinsed, and subsequently incubated with the EpoR antibody (H-194, Santa Cruz) 100 
diluted in PBS and 1.0% Tween 20 was diluted 1:1000 over night at 4°C. The membrane was washed 101 
with PBS, 1.0% Tween 20 and incubated with the secondary antibody (horseradish peroxidase-102 
conjugated goat anti-rabbit antibody, Amersham Pharmacia Biotech) diluted 1:5000 in 0.5% Tween 20 103 
in PBS. After washing the membrane three times, the protein was detected using enhanced 104 
chemiluminescence (ECL, Amersham Pharmacia 
 106 
Biotech). 105 
Statistical analyses.  Description of patient data is given by mean (± SD) unless otherwise 107 
specified. The dependence of different tumour and patient characteristics on plasma and tissue Epo 108 
levels was evaluated by correlation (Wilcoxon rank test, Fisher’s exact probability test). Univariate 109 
proportional hazards and multiple Cox-regression analysis were used for further testing of influences 110 
of any of the descriptors on Epo status. Distribution in HSV and tumour volumes were skewed, thus 111 
logarithmically transformed values were used rather than raw measurements. In all calculations p-112 
value of < 0.05 were considered significant. For statistical analysis StatView 5.0.1 was used. 113 
 114 
 115 
Results 116 
Plasma Epo and haematological parameters. Mean plasma erythropoietin levels were within 117 
normal limits with a mean of 18.8 mU/ml (range 13.6-27.2 mU/ml, normal: 18 mU/ml (range 0-36 118 
mU/ml)). The haematological parameters were within normal limits with mean haematocrit of 43.5% 119 
(range: 35.5-54.0%, normal: 37-55%), haemoglobin of 15.2 g/dl (range: 12.3-10.0 g/dl, normal: 12-18 120 
g/dl). No difference could be found for any of the parameters with respect to the histological groups.  121 
 122 
Tumour hypoxia. The oxygen measurements were comparable to previous findings (13).  More 123 
than 20% of the values were below 10mmHg, 16% of all readings were below 5, 13% of all readings 124 
below 2.5 mmHg, indicating severe hypoxia. The mean of all median pO2
 127 
 values was 27 mmHg 125 
(range: 0-95 mm Hg). 126 
Tissue Epo and EpoR expression. The control values of normal canine tissue Epo expression was 128 
established and is presented in Table 1.  129 
All of the examined tumour tissues were positive for tissue Epo (n=15), and 93% of these also 130 
expressed erythropoietin receptor. Mean tissue Epo levels were 20.0 mU/ml (range: 0.8-65.8 mU/ml, 131 
normal: 0.7-2.7 mU/ml (Table 1). 132 
 133 
Relationship between tumour hypoxia and Epo expression. Significant positive correlations 134 
were found between tissue Epo and the percentages of pO2 values ≤ 10 mmHg (r2=0.93, 95% CI (0.79, 135 
0.98) p=<0.0001), as well as the hypoxic subvolume (r2=0.86, 95% CI (0.61, 0.95), p=<0.0001). 136 
Tumours with median pO2 values ≤ 10 mmHg had significantly higher tissue erythropoietin levels (r2= 137 
-0.65, 95% CI (-0.87, -0.21) p=0.007) than tumours with median pO2
 139 
 values >10 mmHg.  138 
No correlations between the percentages of pO2 values ≤ 10 mmHg, the median pO2
 142 
, or the level of 140 
tissue Epo and plasma erythropoietin concentrations were found.  141 
Multivariate analysis revealed that neither of the haematological parameters nor tumour volumes 143 
influenced the amount of expression of tissue or plasma Epo levels (p>0.27), while the influence of the 144 
median pO2 and the pO2
 146 
 values ≤ 10 mmHg again were found to be important (p<0.03).  145 
 147 
Discussion  148 
Our findings have strong implications for theories regarding Epo biology in spontaneous tumours. The 149 
level of tissue Epo but not plasma Epo expression strongly correlates with the level of tumour 150 
hypoxia, indicating a paracrine role of tissue Epo at the cellular level in the tumour (14). The fact, that 151 
stronger correlation concerning the percentages of low pO2 values and tissue Epo, rather than the 152 
median pO2 value was found, indicates a preferential induction of tissue Epo at very low oxygen 153 
levels. This finding is further supported by the preferential distribution of Epo staining in perinecrotic 154 
(highly hypoxic) regions (15). Furthermore, Arcasoy and colleagues (2005) describe a significant 155 
positive correlation between of regional tissue Epo expression and the hypoxia-marker pimonidazole, 156 
which strongly supports the concomitance of high Epo expression in tissue regions with low pO2
 161 
 (3). 157 
While polarographically measurable low oxygen tension in tumours are known to modulate the 158 
sensitivity of cancer cells to various treatment modalities (5, 7, 16), the effect of  hypoxia-induced 159 
endogenous Epo on treatment outcome has not yet been described. 160 
Intermittent hypoxia is an effective stimulus for Epo synthesis and at high altitudes physiological 162 
plasma Epo rises rapidly, peaking at 20-48 hours, thereafter declining and reaching normal level 163 
values again (12, 17). 164 
The fact that in this study plasma erythropoietin levels did not correlate with tumour hypoxia, may 165 
indicate that in a chronic condition as exerted by a neoplastic disease, either the normal values of 166 
plasma Epo have already been re-established, and/or most of the tissue erythropoietin produced by the 167 
tumour directly binds to its local receptors and the small amounts released into the blood stream do not 168 
influence plasma erythropoietin levels. This finding, together with the coexpression of Epo and EpoR 169 
in tumour cells, is indicative of an autocrine-paracrine activation loop, presenting a potential 170 
therapeutic target in tumours where the Epo/EpoR signalling may be involved in tumour progression 171 
and angiogenesis (4). 172 
 173 
Similar to findings of  other studies (3, 9, 15), 93% of all evaluated tumour tissues in this study were 174 
positive for EpoR. In vitro, hypoxia induces nuclear accumulation of the hypoxia inducible factor 175 
(HIF-1) protein and also upregulates EpoR-protein expression (1, 8, 15), and Molhyedin et al. found in 176 
their study in HNSCC cell lines a hypoxia-inducible upregulation of EpoR rather than tissue Epo (15). 177 
However, in this and other studies the expression of Epo-R is also found in normoxic tumours, 178 
indicating the induction through another oncogenic mechanism (8). 179 
 180 
Epo must act through binding of EpoR which will in turn stimulate downstream signalling in the cell  181 
through the JAK/STAT pathway (9). However, the presence of EpoR does not guarantee its functional 182 
capacity (9) and the Western-blot analysis does not discriminate between EpoR expression localized to 183 
the cell surface and expression localized to the cytoplasmic region of the cell. Although cellular 184 
proliferation and anti-apoptotic protection at suprapharmacologic concentrations of Epo has been 185 
shown in irradiated tumour cells in vitro (15, 18), the cellular signalling mechanism must yet be 186 
proven. The presence of a functional EpoR/Epo-system, however, may contribute to the selection of 187 
cells with diminished apoptotic potential and relative resistance to various cancer treatments (8, 18, 188 
19), and may be further enhanced by exogenous Epo administration. These in vitro findings and the 189 
high percentage of Epo in various canine tumour tissues offer support for the prior raised hypothesis of 190 
a negative effect of administered rHuEpo to anaemic tumour patients (20).  191 
 192 
In conclusion we have demonstrated that there is a strong direct correlation between the prognostic 193 
significant polarographically measured amount of hypoxia (21) and the expression of Epo in canine 194 
malignant tissue. Since increased Epo signalling may be one of the mechanisms by which hypoxia 195 
promotes tumour aggression, the presence of Epo and EpoR need to be quantitatively and functionally 196 
tested as novel prognostic biological parameters in neoplastic tissues. 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
1The abbreviations used are: Epo: erythropoietin; EpoR: erythropoietin receptor; pO2
 207 
: partial pressure 205 
oxygen tension 206 
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 Figure Legends 
 
 
 
Figure 1: Correlations between tissue Epo and the percentages of pO2
 
 values ≤ 10 mmHg: the more 
values of low oxygen tension are present, the higher the tissue Epo expression 
 
Figure 2: Correlations between tissue Epo and the median pO2
 
: the lower the median oxygen pressure, 
the higher the tissue Epo expression 
 
Table 1: Descriptive tumour characteristics 
 
 
Patient 
 
Histology 
 
Location 
 
Volume 
(ccm) 
 
Hypoxic 
subvolume 
(ccm) 
 
 
Median pO2  
(mmHg) 
 
Plasma Epo 
(mU/ml) 
 
Tissue 
Epo 
(mU/ml) 
 
Epo 
receptor 
         
1 Fibrosarcoma Oral cavity 50.3 24.7 5 13.6 50.5 + 
2 Squamous cell carcinoma Oral cavity 13.1 0 31 19.4 28.7 + 
3 Squamous cell carcinoma Oral cavity 9.2 0.5 22 15.0 35.4 + 
4 Hemangiopericytoma Limb 100.5 23.3 30 27.3 23.2 + 
5 Fibrosarcoma Skull 149.7 126.7 2 13.8 65.8 + 
6 Malignant melanoma Oral cavity 26.4 20.1 1 17.3 50.0 - 
7 Malignant melanoma Oral cavity 15.7 0 55 26.7 7.6 + 
8 Squamous cell carcinoma Oral cavity 0.9 0 32 18.5 1.7 + 
9 Squamous cell carcinoma Oral cavity 45.2 0 15 15.4 6.2 + 
10 Fibrosarcoma Oral cavity 13.2 0.13 11 19.8 17.0 + 
11 Hemangiopericytoma Limb 206.5 0 52 14.3 7.0 + 
12 Histiocytic sarcoma Skull 67.8 0 71 18.3 2.8 + 
13 Malignant melanoma Oral cavity 7.6 0 95 21.7 0.8 + 
14 Malignant melanoma Oral cavity 16.2 0 26 20.3 1.2 + 
15 Malignant melanoma Oral cavity 29.9 0 23 15.3 2.0 + 
         
Normal tissue values Lymphnode     2.6  
 (median 1.8) Liver     1.2  
  Muscle     0.7  
  Uterus     2.7  
         
         
 
